www.nterminus.com

Dr. Narian Naidu, is a medical microbiologist with more than 25 years of research on bio active substances and their benefits on human health. As an international expert on protective and therapeutic applications of natural bio active compounds, Dr. Naidu's scientific collaborations extend to Austria, Bulgaria, Denmark, Germany, Hungary, India, Italy, Poland,Netherlands, Sweden, and the United Kingdom. Dr. Naidu also is an elected Fellow of the Royal Society of Medicine (London); The International Society for the study of Vulvo-Vaginal Disease; and the Linnean Society of London. He is an active member of 15 scientific societies including the New York Academy of Sciences, the American Society of Microbiology, the Institute of Food Technologists and the International Association for Food Protection.

After receiving his PH.D. in 1985 from the Faculty of Medicine, Osmania University, India, Dr. Naidu has worked for several agencies, including the World Health Organization, the Hungarian Ministry of Health, the Directorate of Medicine and Health Services of the Government of India, and the Royal Swedish Academy of Sciences. Dr. Naidu has held faculty positions as a professor at several Universities including the Pecs Medical University, Hungary; the Lund University, Sweden; the University of North Carolina at Chapel Hill, USA; and the California State University, USA.

Dr. Naidu is on advisory panels of several multi -national companies, an invited speaker to many universities and scientific organizations around the world. As a prolific writer, he has authored research chapters in more than 25 scientific reference books. Dr. Naidu is also the editor of the highly acclaimed reference volumes, Natural Food Antimicrobial Systems; and Lactoferrin; the two best sellers of the CRC Press.

Early work on Staphylococcal food poisonings and toxic shock syndrome brought International recognition to Dr. Naidu. He received the European Young Scientist Award in 1989 from the European Society for Clinical Microbiology and the Par Excellence Citation for Medical Research in 1992 from the Lund University in Sweden.

Dr. Naidu began his journey with milk lactoferrin research from the mid-1980s in Sweden and published over 50 peer-reviewed scientific articles on this topic. In 1999, he made a major breakthrough in this research area with the invention of 'activated lactoferrin'. This revolutionary technology is commercialized and rewrote the concept of food safety worldwide.

Nikken and Dr. Naidu joined hands to introduce the Next Generation of dietary supplements. Lactoferrin Gold, Osteodenx and CalDenx.

http://www.unboundmedicine.com/medline/ebm/record/19172341/abstract/Milk_ribonuclease_enriched_lactoferrin_induces_positive_effects_on_bone_turnover_markers_in_postmenopausal_women_

Bharadwaj S, Naidu AG, Betageri GV, Prasadarao NV, Naidu AS 
Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women.

[JOURNAL ARTICLE]
Osteoporos Int 2009 Jan 27.

Current treatments for postmenopausal osteoporosis suffer from side effects. Safe and natural milk proteins,

ribonuclease, and lactoferrin promote formation of new capillaries and bone formation. A ribonuclease-enriched lactoferrin

 supplement studied here, demonstrates significant reduction in resorption and increase in formation, towards restoring the

balance of bone turnover within 6 months.
INTRODUCTION: Osteoporosis, a major health issue among postmenopausal women, causes increased bone resorption and

reduced bone formation. A reduction in angiogenesis could also contribute to this imbalance. Current treatments such as

 hormone replacement therapy and bisphosphonates have drawbacks of severe side effects. Milk ribonuclease (RNase) is

known to promote angiogenesis and lactoferrin (LF) to stimulate bone formation by osteoblasts. We examine the effect of

ribonuclease-enriched lactoferrin supplement on the bone health of postmenopausal women.
METHODS: A total of 38 healthy, postmenopausal women, aged 45 to 60 years were randomized into placebo or

RNAse-enriched-LF (R-ELF) supplement groups. The bone health status was monitored by assessing bone resorption markers,

serum N-telopeptides (NTx), and urine deoxypyridinoline (Dpd) crosslinks and serum bone formation markers, bone-specific

alkaline phosphatase (BAP), and osteocalcin (OC).
RESULTS: R-ELF supplementation demonstrated a decrease in urine Dpd levels by 14% (19% increase for placebo) and

serum NTx maintained at 24% of the baseline (41% for placebo), while serum BAP and OC levels showed a 45% and 16%

elevation (25% and 5% for placebo).
CONCLUSIONS: R-ELF supplementation demonstrated a statistically significant reduction in bone resorption and increase in

osteoblastic bone formation, to restore the balance of bone turnover within a short period.